Acute Kidney Injury Pipeline to Progress With Novel and Emerging Drugs for Treatment, Analyzes DelveInsight

Acute Kidney Injury Pipeline

Acute Kidney Injury takes place if the kidneys stop the filtration of the waste products from human blood. There are 25+ companies involved in the development of novel therapies for the treatment of acute kidney injury. The key players operating in the Acute Kidney Injury treatment market include Atox Bio, AM-Pharma, Angion Biomedica, Astellas Pharma, Guard therapeutics and several others.


DelveInsight’s ‘Acute Kidney Injury Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline Acute Kidney Injury therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Acute Kidney Injury pipeline domain.


Key Takeaways from the Acute Kidney Injury Pipeline Report

DelveInsight’s Acute Kidney Injury Pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Acute Kidney Injury treatment. 
The major Acute Kidney Injury companies include Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, Nephraegis Therapeutics, Vasomune, Unicycive, ABIONYX and others are developing novel drug candidates to improve the Acute Kidney Injury treatment landscape.
Key Acute Kidney Injury pipeline therapies in various stages of development include bRESCAP, ANG-3777, EA-230, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), UMC 119 06, Kidney specific amniotic mesenchymal stem cell therapy, RMC 035, SBI-101, QPI-1002, RMC035, MIB-626, RBT-9, Recombinant human alkaline phosphatase, XRx-101, SUL-138, UNI494, Timbetasin, and others.
In March 2022, at the 27th International Conference on Advances in Critical Care Nephrology, AM-Pharma will deliver an overview of the current Phase III REVIVAL study.
In September 2021, AM-Pharma agreed to an exclusive licensing deal with Kyowa Kirin giving Kyowa Kirin the rights to develop and sell ilofotase alfa in Japan.
Angion and Vifor publicly published findings on ANG-3777 clinical trials in 2021, including a Phase II CSA-AKI trial and a Phase III DGF trial.
In December 2021, Researchers at the University of Groningen, the Netherlands and their collaborators, reported a lead compound for the treatment of Acute Kidney Injury (AKI). A new 6-chromanol-derived compound named SUL-138 being developed by Sulfateq BV has shown promise in animal models at treating acute kidney injury.
In terms of development activities for CER-001, ABIONYX marked the continuation of the Phase IIa clinical study, called RACERS, to prevent acute kidney injury in high-risk septic patients, in partnership with the University of Bari.
In February 2022, Renibus Therapeutics completed a USD 15 million extension as part of its Series A financing, led by family offices specializing in biotech investments, closing the round at USD 35 million. Proceeds from the financing will be used to advance Renibus’ pipeline, including the company’s lead candidates, RBT-1 for the prevention of acute kidney injury.
In May 2021, Nephraegis Therapeutics,  developing NPH-022 to prevent and treat Acute Kidney Injury (AKI) launched with a seed investment from Xontogeny, LLC to advance their lead compound through critical preclinical work.
In December 2021, Altasciences has been chosen by XORTX Therapeutics Inc. to conduct a pharmacokinetic bridging study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with COVID-19.
In June 2021, KBI Biopharma entered into a manufacturing agreement with AM Pharma, particularly concerning AM Pharma’s recAP program potentially being investigated for the treatment of sepsis-associated acute kidney injury.


Request a sample and discover the recent breakthroughs happening  Acute Kidney Injury pipeline landscape in  @ Acute Kidney Injury Pipeline Outlook


The Acute Kidney Injury pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Acute Kidney Injury products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Acute Kidney Injury pipeline landscape.

Acute Kidney Injury Overview

Acute Kidney Injury (AKI), commonly known as Acute Renal Failure (ARF), is a condition characterised by progressive azotemia with or without oliguria over several hours or days. Acute Kidney Injury is typically characterised as a sudden loss in renal function, clinically manifested as a reversible acute rise in nitrogen waste products evaluated by blood urea nitrogen and serum creatinine levels over hours to weeks. Acute Kidney Injury causes a sudden decrease in renal function, resulting in waste product retention, electrolyte abnormalities, and volume status changes. There are three Acute Kidney Injury stages: prerenal, postrenal, and intrinsic renal.

Many people with Acute Kidney Injury are asymptomatic, while others have generalised non-specific Acute Kidney Injury symptoms such as nausea, vomiting, weakness, dizziness, lower back pain, passing less urine than usual, unexplained loss of appetite, feeling sick or vomiting, feeling short of breath, and swelling of the legs or other body parts.

Acute Kidney Injury diagnosis is generally based on an increase in serum creatinine and/or a decrease in urine output.


Find out more about Acute Kidney Injury medications @ Acute Kidney Injury Guidelines


A snapshot of the Acute Kidney Injury Pipeline Drugs mentioned in the report:







Angion Biomedica/Vifor Pharma

Phase II

Proto oncogene protein c met stimulant


Ilofotase alfa

AM Pharma

Phase III

Endotoxin inhibitors; Enzyme replacements



Astellas Pharma

Phase II

Peroxisome proliferator-activated receptor delta modulators


Ruconest (Conestat alfa)

Pharming Technologies

Phase II

Complement C1 inhibitor protein replacements; Complement C1r inhibitors; Complement C1s inhibitors



Guard Therapeutics

Phase II

Alpha 1 microglobulin replacements



Sentien Biotechnologies

Phase I/II

Stem cell modulators



RegeneRx Biopharmaceuticals


Actin modulators; Amyloid inhibitors




Acute Kidney Injury Therapeutics Assessment

The Acute Kidney Injury Pipeline report proffers an integral view of the Acute Kidney Injury emerging novel therapies segmented by Stage, Product Type,  Molecule Type,  Mechanism of Action, and Route of Administration.


Scope of the Acute Kidney Injury Pipeline Report 

Coverage: Global 
Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Therapeutics Assessment By Route of Administration: Oral, Parenteral, Subcutaneous, Topical, Intravitreal, Subretinal, Topical
Therapeutics Assessment By Molecule Type: Gene therapies, Small molecule, Polymers, Peptides, Monoclonal antibodies
Therapeutics Assessment By Mechanism of Action: Alpha 1 microglobulin replacements, Antioxidants, Free radical scavengers, Haemoglobin inhibitors, Decyclizing heme oxygenase inhibitors, Immunomodulators, Virus replication inhibitors, CD28 antigen modulators, Immunomodulators, Cell replacements, RNA interference, Tumour suppressor protein p53 inhibitors
Key Acute Kidney Injury Companies: Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Pharming Technologies, and others.
Key Acute Kidney Injury Pipeline Therapies: bRESCAP, ANG-3777, EA-230, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), and others.


Dive deep into rich insights for drugs for Acute Kidney Injury, visit @ Acute Kidney Injury Emerging Therapies


Table of Contents




Executive Summary


Acute Kidney Injury Pipeline: Overview


Analytical Perspective In-depth Commercial Assessment


Acute Kidney Injury Pipeline Therapeutics


Acute Kidney Injury Pipeline: Late Stage Products (Phase III)


Ilofotase alfa: AM-Pharma


Acute Kidney Injury Pipeline: Late Stage Products (Phase III)


Acute Kidney Injury Pipeline: Mid Stage Products (Phase II)


ANG-3777: ANG-3777


Acute Kidney Injury Pipeline: Early Stage Products (Phase  I)


RBT-9: Renibus Therapeutics


Therapeutic Assessment


Inactive Products


Company-University Collaborations (Licensing/Partnering) Analysis


Key Companies


Key Products


Unmet Needs


Market Drivers and Barriers


Future Perspectives and Conclusion


Analyst Views




For further information on the Acute Kidney Injury pipeline therapeutics, reach out@ Drugs for Acute Kidney Injury


About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States

Are you a market researcher?

Explore our research partnership options.


Find out what people like and dislike about your competitors, and compare it with your brand performance.

Competitor Analyzer

Generated by Feedzy
%d bloggers like this: